Venkatraman Rajagopalan, Karthik Krishnamoorthy, Pushparani Anand, Mahalakshmi Annadurai
SRM Medical College Hospital and Research Centre, Department of Anesthesia, Chennai, India.
SRM Medical College Hospital and Research Centre, Department of Anesthesia, Chennai, India.
Braz J Anesthesiol. 2018 Jan-Feb;68(1):42-48. doi: 10.1016/j.bjan.2017.04.019. Epub 2017 May 22.
Shivering, a common intraoperative problem under spinal anesthesia increases the oxygen consumption considerably and is uncomfortable and distressing to the patient, anesthesiologist as well as surgeon. The present study was designed to explore the effectiveness of tramadol, clonidine and dexmedetomidine in the treatment of post spinal anesthesia shivering and to look for their adverse effects.
This prospective, randomized, double blinded control study was done on 90 patients who developed shivering under spinal anesthesia. They were randomly allocated into three groups with Group T receiving tramadol 1 mg.kg, Group C getting clonidine 1 mcg.kg and Group D patients receiving dexmedetomidine 0.5 mcg.kg. The time taken to control shivering, recurrence rate, hemodynamic variables, sedation score and adverse effects were observed.
Dexmedetomidine was faster in the control of shivering in 5.7 ± 0.79 minutes (min) whereas tramadol took 6.76 ± 0.93 min and clonidine was slower with 9.43 ± 0.93 min. The recurrence rate was much lower in the dexmedetomidine group with 3.3% than for clonidine (10%) and tramadol (23.3%) group. The sedation achieved with dexmedetomidine was better than clonidine and tramadol. The tramadol group had more cases of vomiting (four) and dexmedetomidine group had six cases of hypotension and two cases of bradycardia. Two of the clonidine patients encountered bradycardia and hypotension.
Dexmedetomidine is better than tramadol and clonidine in the control of shivering because of its faster onset and less recurrence rate. Though complications are encountered in the dexmedetomidine group, they are treatable.
寒战是脊髓麻醉下常见的术中问题,会显著增加氧耗,给患者、麻醉医生和外科医生带来不适与痛苦。本研究旨在探讨曲马多、可乐定和右美托咪定治疗脊髓麻醉后寒战的有效性,并观察其不良反应。
本前瞻性、随机、双盲对照研究纳入了90例脊髓麻醉下发生寒战的患者。他们被随机分为三组,T组接受曲马多1mg/kg,C组给予可乐定1μg/kg,D组患者接受右美托咪定0.5μg/kg。观察控制寒战所需时间、复发率、血流动力学变量、镇静评分及不良反应。
右美托咪定控制寒战更快,用时5.7±0.79分钟,而曲马多用时6.76±0.93分钟,可乐定较慢,用时9.43±0.93分钟。右美托咪定组复发率低得多,为3.3%,低于可乐定组(10%)和曲马多组(23.3%)。右美托咪定的镇静效果优于可乐定和曲马多。曲马多组呕吐病例较多(4例),右美托咪定组有6例低血压和2例心动过缓。2例可乐定患者出现心动过缓和低血压。
右美托咪定在控制寒战方面优于曲马多和可乐定,因其起效更快且复发率更低。尽管右美托咪定组出现了并发症,但均可治疗。